Biora Therapeutics
Yahoo Finance • last year
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biora Therapeutics, Inc. - BIOR
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biora Therapeutics, Inc. (“Biora” or the “Company”) (NASDAQ: BIOR). Such investors are advised to contact Robert S. Willoughby... Full story
Yahoo Finance • last year
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows potential for liver-targeted delivery... Full story
Yahoo Finance • last year
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the t... Full story
Yahoo Finance • last year
Biora Therapeutics to Submit Updated IND Application for BT-600
Biora anticipates remaining on track with its phase 1 clinical trial execution timeline Update to include supplemental information and allow additional time to complete regulatory review SAN DIEGO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Bio... Full story
Yahoo Finance • last year
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral... Full story
Yahoo Finance • last year
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis IND application is supported by robust clinical device function data SAN DIEGO, Sept. 2... Full story
Yahoo Finance • last year
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023 Transaction results in a debt reduction of $... Full story
Yahoo Finance • last year
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced achievement of its device performance targets for the company’s BioJet™... Full story
Yahoo Finance • last year
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
NaviCap™ targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device BioJet™ systemic oral delivery platform device development achieved function... Full story
Yahoo Finance • last year
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report financial results and provide a corporate update for... Full story
Yahoo Finance • last year
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement with a large diagnostics company for t... Full story
Yahoo Finance • last year
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to se... Full story
Yahoo Finance • last year
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today shared detailed results from its preclinical study titled “Evaluation of the Pharma... Full story
Yahoo Finance • last year
Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced the closing of its previously announced regist... Full story
Yahoo Finance • last year
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced that it has entered into a definitive agreemen... Full story
Yahoo Finance • 2 years ago
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023 Preclinical testing for the BioJet™ platform is advancing both internally and with p... Full story
Yahoo Finance • 2 years ago
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelma... Full story
Yahoo Finance • 2 years ago
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD Innovate: Product Development for Crohn’... Full story
Yahoo Finance • 2 years ago
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report fourth quarter and full year ended December 31, 2022... Full story
Yahoo Finance • 2 years ago
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from preclinical testing of its PGN-OB1 program, repo... Full story
